In the article by Furie et al, “Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation: A Science Advisory for Healthcare Professionals From the American Heart Association/American Stroke Association,” which published ahead of print on August 2, 2012, and appeared in the December 2012 issue of the journal (Stroke. 2012;43:3442–3453), several corrections were needed.
On page 3445, in the first column, the fifth paragraph, text has been added to the end of the paragraph. The paragraph now reads, “…were included in the primary report on RE-LY.26 Additional events were identified after the RE-LY trial database was locked. Based on the updated results, the net clinical benefit for dabigitran 110 mg twice daily was 7.34 per 100 person years versus 7.11 for dabigitran 150 mg twice daily and 7.91 for warfarin.27”
On page 3445, in the second column, the first paragraph, the last sentence, the reference number has changed to maintain numerical order. The sentence read, “…P for interaction <0.001).27” It has been changed to read, “…P for interaction <0.001).28”
On page 3445, in the second column, the second paragraph, the second sentence, the reference number has changed to maintain numerical order. The sentence read, “…rate of MI between treatment arms were no longer significant.28” It has been changed to read, “…rate of MI between treatment arms were no longer significant.27”
On page 3452, in the second column, to maintain numerical order, reference 27 has been changed to reference 28, and reference 28 has been changed to reference 27.
These corrections have been made to the current online version of the article, which is available at http://stroke.ahajournals.org/content/43/12/3442.full.pdf.
- © 2013 American Heart Association, Inc.